VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has provided an update on its strategy to implement U.S. Food and Drug Administration (FDA)-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines, and significantly reduce animal testing.
VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates, and bispecific antibody-drug conjugates. The company said its lead BiTAC-TCE and bsADC candidates were also evaluated using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. The panel required about 10 mice in total, compared with an estimated 200 or more for comparable in vivo efficacy studies. Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company’s dual-targeting approach and demonstrating how its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance.
This development matters because it addresses two critical challenges in oncology drug development: the high cost and long timelines of preclinical testing, and growing ethical concerns about animal experimentation. By adopting FDA-aligned NAMs, VERAXA aims to bring therapies to patients faster while maintaining rigorous safety and efficacy standards. If successful, the approach could serve as a model for the broader biotech industry, potentially reshaping how preclinical research is conducted.
Investors and industry watchers can track further updates on VERAXA’s progress through the company’s newsroom at http://ibn.fm/VRXA. The full press release is available at https://ibn.fm/9YRJw.
VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL).
For more information about the company, visit VERAXA Biotech (NASDAQ: VRXA). BioMedWire is a specialized communications platform focused on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, and social media distribution. For more information, visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website: https://www.BioMedWire.com/Disclaimer.
